The Second Circuit upheld the insider trading conviction of Robert Schulman, a former patent attorney at Hunton & Williams, convicted in 2017 for tipping his investment adviser, Tibor Klein, to Pfizer’s planned acquisition of King Pharmaceuticals in 2010. Schulman appealed a decision rejecting his motion to vacate his conviction on grounds of insufficient evidence. In affirming that decision, the Second Circuit concluded that the jury was not required to credit Schulman’s testimony that he intended only to brag about his knowledge of the merger to a friend.
January 10, 2019
Second Circuit upholds insider trading conviction of former lawyer
Related by Topic
NY Attorney General settles with Emergent for $900,000 and charges former CEO with insider trading
January 21, 2026
News Alert
Federal prosecutors in Massachusetts charge New Jersey biostatistician with insider trading
January 19, 2026
News Alert
Former Doximity executive pleads guilty in the Southern District of New York for insider trading
January 13, 2026
News Alert